Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + Formoterol vs Salmeterol + Fluticasone in COPD
NCT00239421Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2003
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial of tiotropium and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Forced Expiratory Volume in 1 Second Area Under the Curve (0-12 hours) at 6 weeks and Peak Forced Expiratory Volume in 1 Second at 6 weeks. Started Nov 2003; status: completed.
02
Drugs
tiotropiumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00239421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239421.